Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS

Advances in Experimental Medicine and Biology

Volumn 655, Issue , 2009, Pages 189-242

  Cafaro, Aurelio ^b   Macchia, Iole ^b   Maggiorella, Maria Teresa ^b   Titti, Fausto ^b   Ensoli, Barbara ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BACTERIAL VECTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; GENE PRODUCT; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROSPHERE; NEF PROTEIN; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; PLASMID DNA; POL PROTEIN; POLYGLACTIN; REV PROTEIN; SUBUNIT VACCINE; TRANSACTIVATOR PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; ILLNESS TRAJECTORY; IMMUNIZATION; INFECTION PREVENTION; INTERNATIONAL COOPERATION; LISTERIA MONOCYTOGENES; MYCOBACTERIUM BOVIS; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; SALMONELLA; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINE FAILURE; VACCINE PRODUCTION; VIRUS LIKE AGENT; ANIMAL; CHEMISTRY; GENE VECTOR; GENETICS; HEALTH; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFECTION CONTROL; METABOLISM; PLASMID; REVIEW; VACCINATION; VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; COMMUNICABLE DISEASE CONTROL; DNA; DRUG DESIGN; GENETIC VECTORS; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM; PLASMIDS; VACCINATION; VIRUSES; WORLD HEALTH;

EID: 77954663191     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1132-2_14     Document Type: Article

References (484)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2007.
2. Kresge KJ. Establishing accurate estimates of HIV incidence rates arc critical to the successof prevention trials. International AIDS VAccine Initiative (IAVI) Report Vol. 11(issue 3). 2007.
3. UNAIDS and WHO. AIDS Epidemic Update. Geneva, Switzerland: UNAIDS/WHO, 2006 (http:// data.una ids.orgipub/EpiRepon/2006/03-Introduction.2006- EpiUpdate3ng.pdf) accessed 2007).
4. Walker BD. Rosenberg ES. Containing HIV after infection . Nat Med 2000; 6:1094-1095.
5. Rowland-Jones SL. Timeline: AIDS pathogenesis: what have two decades of HIV research taught us? Nat Rev Immunol 2003; 3:343-348. (Pubitemid 37328686)
6. McMichael AJ. HIV vaccines. Annu Rev Immunol 2006; 24:227-255 .
7. Spearman P. Current progress in the development of HIV vaccines. Curr Pharm Des 2006; 12:1147-1167.
8. HIV Vaccine trials network (http://www.hvm.orgltrials).
9. IAVI Database of AIDS Vaccines In Human Trials (http://www. iavLorgitrialsdb).
10. Butler IF. Pandrea I, Marx PA et al, HIV genetic diversity: biological and public health consequences. Curr HIV Res 2007; 5:23-45. (Pubitemid 46062357)
11. Korber B, Gaschen B. Yusim K et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58:19-42. (Pubitemid 33070762)
12. Wei X. Decker JM. Wang S et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422 :307-312. (Pubitemid 36378357)
13. Asquith B, McLean AR. In vivo CD8+ T-cell control of immunode6ciency virus infection in humans and macaques. Proc Natl Acad Sci USA 2007; 104:6365-6370. (Pubitemid 47186100)
14. Vlasak J. Ruprecht RM. AIDS vaccine development and challenge viruses: getting real. AIDS 2006; 20:2135-2140. (Pubitemid 44684703)
15. Fackler OT, Alcover A. Schwartz O. Modulation of the immunological synapse: a key to HIV-1 pathogenesis? Nat Rev Immunol 2007; 7:310-317. (Pubitemid 46480952)
16. Goulder PJ. Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004 ; 4:630-640. (Pubitemid 39025048)
17. Evans DT. Desrosiers RC. Immune evasion strategies of the primate lentiviruses. Inununol Rev 2001; 183:141-158. (Pubitemid 34015445)
18. Frahm N, Brander C. HIV viral diversiry and escape from cellular immunity. Curr Infect Dis Rep 2007; 9:161-166. (Pubitemid 46416058)
19. McKay PF, Barouch DH. SchmitzJE et al, Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infeered monkeys is prevented by vaccination. J Yirol 2003 ; 77:4695-4702. (Pubitemid 36402819)
20. Kulkarni PS. Butera ST. Duerr AC. Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 2003; 5:87-103. (Pubitemid 36873898)
21. Goh WC, Markee J. Akridge RE et al. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T-cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis 1999; 179:548-557. (Pubitemid 30016137)
22. Hoffmann R. Gene expression patterns in human and mouse Bvcell development. Curr Top Microbiol Immunol 2005; 294:19-29. (Pubitemid 41491248)
23. Fowke KR. Nagelkerke NJ, Kimani J et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348:1347-1351. (Pubitemid 26383775)
24. Kaul R. Rowland-Jones SL, Kimani J et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest 2001; 107:341-349. (Pubitemid 32157966)
25. Kaul R. Rutherford J, Rowland-jones SL et al. HIV-1 Env-specificcytotoxic T-lymphocyte responses in exposed, uninfected Kenyan sex workers: a prospect ive analysis. AIDS 2004; 18:2087-2089. (Pubitemid 39463364)
26. Clerici M, Levin JM, Kessler HA. et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 1994; 271:42-46. (Pubitemid 24020578)
27. Pinto LA, Sullivan J, BerzofskyJA et al. ENV-specific cytotoxic T-lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body Auids.J Clin Invest 1995; 96:867-876.
28. Liu R. Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377. (Pubitemid 26272077)
29. Lopalco L, Pasrori C, Barassi C et al. Heterogeneity in exposed uninfected individuals. J Biol Regul Homeost Agents 1997; 11:27-31. (Pubitemid 27503820)
30. Schenal M. Lo CS. Fasano F et al. Distinct patterns of HIV-specific memory T-Iymphocytes in HIV-cxposed uninfected individuals and in HIV-1nfected patients. AIDS 2005; 19:653-661. (Pubitemid 40593070)
31. Kaul R. Plummer FA. Kimani J et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nalrobt,.J Immunol 2000 ; 164:1602-1611. (Pubitemid 30067280)
32. Furci L, Lopalco L, Loverro P et al. Noncytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T-lymphocytes from HIV-exposed-uninfecred individuals. AIDS 2002; 16:1003-1008. (Pubitemid 34499423)
33. Stranford SA. Skurnick J,Louria D et al Lack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic ami-HIV response. Proc Natl Acad Sci USA 1999; 96:1030-1035. (Pubitemid 29072178)
34. Alimomi JB, Koesters SA, Kimani J, et al. CD4+ Tvcell responses in HIV-exposed seronegative women are qualitatively distinct from those in HIV-Infected women, J Infect Dis, 2005, 191: 20-24. (Pubitemid 40041395)
35. Momoya CJ, Velilla PA. Chougner C et al Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 2006; 120:138-146. (Pubitemid 44080673)
36. Hirbod T. Broliden K. Mucosal immune responses in the genital tract of HIV-1 -exposed uninfeceed women. J Intern Med 2007 ; 262 :44-58. (Pubitemid 47000632)
37. Mazzoli S. Lopalco L. Salvi A et al. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons.J Infect Dis 1999; 180:871-875. (Pubitemid 29411381)
38. Kaul R. Trabattoni D. Bwayo JJ et al, HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 1999; 13:23-29. (Pubitemid 29078060)
39. Dorak MT, Tang J. Penman-Aguilar A et al Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples. Lancet 2004; 363:2137-2139. (Pubitemid 38844156)
40. Wang CY, Cusack JC Jr, Liu R et al Control of inducible chemoresistance: enhanced anti-rumor therapy through increased apoptosis by inhibition of NF-kappa B. Nat Med 1999; 5:412-417. (Pubitemid 29180579)
41. Shearer GM, Pinto LA. Clerici M. Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS. Immunol Today 1999; 20:66-71. (Pubitemid 29136630)
42. Buchbinder SP. Katz MH. Hessol NA et al Long-term HIV-1 infection without immunologic progression. AIDS 1994; 8:1123-1128. (Pubitemid 24228710)
43. Keet IP. Krol A. Klein MR et al Characteristics of long-term asymptomatic infection with human immunodeficiency virus type 1 in men with normal and low CD4+ cell counts. J Infect Dis 1994; 169:1236-1243. (Pubitemid 24164585)
44. Lefrere JJ. Morand-Joubert L. Mariotti M et al. Even ind ividuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 1997; 90:1133-1140. (Pubitemid 27314149)
45. Sheppard HW, Lang W, Ascher MS et al The characterization of nonprogressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993; 7:1159-1166. (Pubitemid 23270961)
46. Alexander L. Weiskopf E, Greenough TC et al. Unusual polymorph isms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol 2000; 74:4361-4376. (Pubitemid 30214444)
47. Deacon NJ. Tsykin A. Solomon A et al.. Genomic structure of an attenuated quasi species of HIV-1 from a blood tran sfusion donor and recipients. Science 1995; 270 :988-991.
48. Hassaine G. Agostini I. Candotti D et al Characterization of human immunodeficiency virus type I vif gene in long-term asymptomatic individuals. Virology 2000 ; 276:169-180.
49. Kirchhoff F, Greenough TC. Breeder DB et al. Brief report: absence of intact nefsequences in a long-term survivor with non progressive HIV-1 infection. N Engl J Med 1995; 332:228-232.
50. Lum JJ. Cohen OJ. Nie Z et al. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoprotsis, J Clin Invest 2003 ; 111:1547-1554. (Pubitemid 38063287)
51. Wang B, Ge YC. Palasamhiran P et al Gene defects clustered at the Cvterminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma. Virology 1996; 223 :224-232. (Pubitemid 26302062)
52. Yamada T. Iwamoto A. Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. Arch Virol 2000 ; 145:1021-1027. (Pubitemid 30332619)
53. Daniel MD. Kirchhoff F, Czajak SC et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258 :1938-1941. (Pubitemid 23026733)
54. Sernicola L. Corrias F. Koanga-Mogtomo ML et al Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen. Virology 1999; 256:291-302. (Pubitemid 29393364)
55. Titti F, Sernicola L. Geraci A et al. Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys.J Gen Virol 1997; 78:2529-2539. (Pubitemid 27469996)
56. Learmont JC. Geczy AF, Mills J et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 1999; 340:1715-1722. (Pubitemid 29252599)
57. Baba TW, Liska V. Khimani AH et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infam and adult macaques. Nat Med 1999; 5:194-203. (Pubitemid 29068527)
58. Johnson RP, Lifson JD. Czajak SC et al. Highly attenuated vaccine strain s of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 1999; 73:4952-496 1. (Pubitemid 29246756)
59. Koff WC. Johnson PR, Watkins DI et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006: 7:19-23. (Pubitemid 41823864)
60. Cohen OJ, Vaccarezza M, Lam GK et al. Heterozygosity for a defectivegene for CC chemokine receptor 5 is not the sole determinant for the Immunol ogic and virologic phenotype of HIV-Infected long-term nonprogressors. J Clin Invest 1997: 100:1581-1589. (Pubitemid 27425786)
61. Gonzalez E. Kulkarni H, Bolivar H et al. The influence of CCL3Ll gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005: 307:1434-1440. (Pubitemid 40321934)
62. Kaslow RA. Carrington M. Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996: 2:405-411. (Pubitemid 26193012)
63. Kiepiela P. Ngumbela K, Thobakgale C et al. CD8+ T'-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007: 13:46-53. (Pubitemid 46067385)
64. Harari A, Cellerai C. Enders FB et al. Skewed association of polyfunctional anrigen-specificCD8 T-cell populations with HLA-B genotype. Proc Nacl Acad Sci USA 2007: 104:16233-16238. (Pubitemid 350099390)
65. Collins KL, Chen BK. Kalams SA et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T-lymphocytes. Nature 1998: 391:397-401. (Pubitemid 28093515)
66. Martin MP, Qi Y, Gao X et al. Innate partnership of HLA-B and KIR3DLl subtypes against HIV-1. Nat Genet 2007: 39:733-740. (Pubitemid 46848586)
67. Altfeld M. Goulder P. 'Unleashed' natural killers hinder HIV. Nat Genet 2007: 39:708-710. (Pubitemid 46848581)
68. Betts MR, Nason MC. West SM et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-celis. Blood 2006: 107:4781-4789. (Pubitemid 43882629)
69. Pantaleo G. Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006: 6:417-423.
70. Zimmerli SC. Harari A, Cellerai C et al. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T-celis support CD4-independent proliferation of HIV-1-specific CD8 T-cells, Proc Natl Acad Sci USA 2005: 102:7239-7244. (Pubitemid 40696363)
71. Saez-Cirion A. Lacabaratz C. Lambotte O et al. HIV controllers exhibit potent CD8 T-cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T-lymphocyte activation phenotype. Proc Nacl Acad Sci USA 2007: 104:6776-6781. (Pubitemid 47175577)
72. Arrode G, Finke JS. Zebroski H et al, CD8+ T-cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses. Eur J Immunol 2005; 35:159-170.
73. Levy JA. The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol 2003; 24:628-632. (Pubitemid 37485911)
74. Cao J. McNevin J. Malhotra U et al. Evolution of CD8+ T-cell immunity and viral escape following acute HIV-1 infection.J Immunol 2003; 171:3837-3846. (Pubitemid 37254590)
75. Chun TW, justemcnr JS. Moir S et al. Suppression of HIV replication in the resting CD4+ T-cell reservoir by autologous CD8+ T-cells: implications for the development of therapeutic strategies. Proc Natl Acad Sci USA 2001; 98:253-258. (Pubitemid 32095896)
76. Norris PJ, Rosenberg ES. CD4(+) T-helper cells and the role they play in viral control. J Mol Med 2002: 80:397-405. (Pubitemid 34754205)
77. Kannanganat S, Ibegbu C, Chennareddi L et al. Multiple-cyeoklne-producing antiviral CD4 T-cells are functionally superior to slngle-cyrokine-produclng cells.J Virol 2007: 81:8468-8476. (Pubitemid 47242819)
78. Decks SG, WalkerBD. Human immunodeficiencyvirus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406-416. (Pubitemid 47418678)
79. Dolan MJ, Kulkarni H. Camargo JF et al. CCL3Ll and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007: 8:1324-1336. (Pubitemid 350131170)
80. Fellay J, Shianna ICY, Ge D et al. A whole-genome association study of major determinants for host control of HIV- 1. Science 2007: 317:944-947. (Pubitemid 47301321)
81. Carotenuto P. Looij D. KeldermansL et al. Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998; 12:1591-1600. (Pubitemid 28418328)
82. Pilgrim AK. Pantaleo G, Cohen OJ et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-rerm-nonprogressive infection. J Infect Dis 1997: 176:924-932. (Pubitemid 27411034)
83. Bailey JR. Lassen KG. Yang HC et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active anti-retroviral therapy. J Virol 2006; 80:4758-4770.
84. Humbert M, Antoni S, Brill B et al. Mimotopes selected with antibodies from HIV-1-neurralizing long-term nonprogressor plasma. Eur J Immunol 2007: 37:501-515. (Pubitemid 46915589)
85. Hirsch VM, What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS? AIDS Rev 2004: 6:40-53. (Pubitemid 38607540)
86. Kaur A, Grant RM, Means RE et al. Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol 1998; 72:9597-9611. (Pubitemid 28520823)
87. Paiardini M, Cervasi B, Sumpter B et al. Perturbations of cell cycle control in T-cells contribute to the different outcomes of simian immunodeficiency virus infection in rhesus macaques and sooty mangabeys. J Virol 2006; 80:634-642. (Pubitemid 43062876)
88. Silvestri G. Naturally SIV-infected sooty mangabeys: are we closer to understanding why they do not develop AIDS ?J Med Primatol 2005; 34:243-252. (Pubitemid 41179586)
89. Estes JD, Li Q. Reynolds MR et al. Premature induct ion of an immunosuppressive regulatory T-cell response during acute simian immunodeficiency virus infection.J Infect Dis 2006; 193:703-712. (Pubitemid 43271504)
90. Kornfeld C, Ploquin MJ, Pandrea I et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J Clin Invest 2005 ; 115:1082-1091. (Pubitemid 40489413)
91. Rouse BT, Sarangi PP, Suvas S. Regulatory T-cells in virus infections. Immunol Rev 2006; 212:272-286.
92. Gordon SN, Klatt NR, Bosinger SE et al. Severe Depletion of Mucosal CD4+ T-Cells in AIDS-Free Simian Immunodeficiency Virus-Infected Sooty Mangabeys.J Immunol 2007; 179:3026-3034.
93. Milush JM, Reeves JD, Gordon SN et al. Virally induced CD4+ T-cell depletion is not sufficient to induce AIDS in a natural host, J Immunol, 2007, 179: 3047-3056
94. Pandrea IV, Gautam R, Ribeiro RM et al. Acute loss of intestinal CD4+ T-cells is not predictive of simian immunodeficiency virus virulence.J Immunol 2007; 179:3035-3046.
95. Letvin NL, Huang Y, Chakrabarti BK et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.J Virol 2004; 78:7490-7497. (Pubitemid 38915894)
96. Letvin NL, MascolaJR, Sun Y et al. Preserved CD4+ central memory T-cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312:1530-1533. (Pubitemid 43865893)
97. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004; 10:806-810. (Pubitemid 39070851)
98. Sun Y, Schmitz JE, Buzby AP et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys alter simian immunodeficiency virus challenge.J Virol 2006; 80:10950-10956. (Pubitemid 44706536)
99. Humbert M, Dietrich U. The role of neutralizing antibodies in HIV infection. AIDS Rev 2006 ; 8:51-59. (Pubitemid 44043554)
100. Johnston MI, Fauci AS. An HIV vaccine-evolving concepts. N Engl J Med 2007; 356:2073-2081.
101. Centlivre M, Sala M, Wain-Hobson S et al. In HIV-1 pathogenesis the die is cast during primary infection. AIDS 2007; 21:1-11. (Pubitemid 44912531)
102. Dandekar S. Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep 2007; 4:10-15. (Pubitemid 46555246)
103. Phogat S, Wyatt RT, Karlsson Hedesram GB. Inhibition of HIV-1 entry by antibod ies: potential viral and cellular targets. J Intern Med 2007; 262:26-43. (Pubitemid 47000631)
104. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of svolutionary titans. Proc Natl Acad Sci USA 2005; 102:14943-14948. (Pubitemid 41513316)
105. Panrophler R, Burton DR. GP120: target for neutralizing HIV-1 ant ibodies. Annu Rev Immunol 2006; 24:739-769.
106. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004; 4:199-210. (Pubitemid 38339086)
107. Ruprecht RM, Ferranrelli F, KitabwallaM et al. Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine 2003; 21:3370-3373. (Pubitemid 36792088)
108. Trkola A, Kuster H, Rusert P et al. Delay of HIV-1 rebound alter cessation of anti-retroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622. (Pubitemid 40868301)
109. Haynes BE Moody MA, Verkoczy L et al. Antibody polyspecificiry and neutralization of HIV-1: a hypothesis. Hum Antibodies 2005; 14:59-67.
110. Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006; 6:930-939. (Pubitemid 44851735)
111. ass-Chapman MM, Hayman A, Newton P et al. Development of the antibody response in acute HIV-1 infection. AIDS 2004; 18:371-381. (Pubitemid 38365863)
112. Yamamoto H, KawadaM, Takeda A et al. Post-infection immunodeficiency virus control by neutralizing antibodies. PLoS ONE 2007; 2:e540.
113. Holl V, Peressin M, Decoville T et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006; 80:6177-6181. (Pubitemid 43849196)
114. de Arruda LB, Chikhlikar PR, August JT et al. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 2004; 112:126-133.
115. Evans TG, Frey S, Israel H et al. Long-term memory Bvcell responsesin recipients of candidate human immunodeficiency virus rypc 1 Vaccine s. Vaccine 2004; 22:2626-2630. (Pubitemid 38757366)
116. Huber M, Trkola A, Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007; 262:5-25. (Pubitemid 47000630)
117. Ahmad A, Menezes J, Antibody-dependent cellular cytotoxicity in HIV infections. FASEBJ 1996; 10:258-266. (Pubitemid 26079945)
118. Bjorling E. Broliden K. Bernardi D et al. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. Proc Natl Acad Sci USA 1991; 88:6082-6086. (Pubitemid 21914890)
119. Brenner BG. Gryllis C, Wainberg MA. Role of antibody-dependent cellular cytotoxicity and lymphokine-acttvared killer cells in AIDS and related diseases. J Leukoc Biol 1991; 50:628-640.
120. Broliden K, von GA. Persson C et al. Identification of cross-reactive antigenic target regions for HIV type 1 -specific antibody-dependent cellular cytotoxicity. AIDS Res Hum Retroviruses 1996; 12:1699-1702. (Pubitemid 26424048)
121. Broliden PA, Ljunggren K. Hinkula Jet al. A monoclonal antibody to human immunodeficiencyvirus type 1 which mediates cellular cytotoxicity and neutralization. J Virol 1990; 64:936-940. (Pubitemid 20032716)
122. Ljunggren K, Broliden PA. Morfeldt-Manson L et al. IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol 1988; 73:343-347.
123. von Gegerfelr A. Nilsson C, Purkonen P et al. Broadly reactive HIV-2 and SIVmac specific antibody-dependent cellular cytotoxicity in immunized and infected cynomolgus monkeys. Vaccine 1994; 12:1203-1208.
124. Gomez-RomanYR. Patterson LJ,VenzonD et al.Vaccine -elicited antibodiesmediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251.J Immunol 2005; 174:2185-2189. (Pubitemid 40223963)
125. Hessell AJ, Hangartner L, Hunter M et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104. (Pubitemid 47373775)
126. Emini EA, Koff WC. AIDS/HIV. Developing an AIDS Vaccine: need, uncertainty, hope. Science 2004; 304:1913-1914. (Pubitemid 38822172)
127. Garber DA. Silvestri G. Feinberg MB. Prospects for an AIDS Vaccine: three big questions. no easy answers. Lancet Infect Dis 2004; 4:397-413. (Pubitemid 38844125)
128. Robinson HL. Amara RR. Tvcell Vaccines for microbial infections. Nat Med 2005; 11 :S25-S32.
129. Douek DC. Kwong PD, Nabel GJ. The rational design of an AIDS Vaccine . Cell 2006; 124:677-681. (Pubitemid 43261441)
130. Cocchi F. DeVico AL, Garzino-Demo A et al. Identification of RANTES. MIP-1 alpha and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T-cells. Science 1995; 270:1811-1815.
131. Walker CM, Steimer KS. Rosenthal KL et al. Identification of human immunodeficiency virus (HIV) envelope type-specific T-helper cells in an HIV-Infected individual. J Clin Invest 1988; 82:2172-2175. (Pubitemid 19054969)
132. Goonedlleke N. Moore S. Dally L et al. Induction of multifunctional human immunodeficiencyvirus type 1 (HIV-1 )-specificT-cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored Vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epiropes, J Virol 2006; 80:4717-4728.
133. McMichael A. Hanke T. The quest for an AIDS Vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol 2002; 2:283-291. (Pubitemid 37323228)
134. Tobery TW; Dubey SA, Anderson K et al. A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T-cell responses in Ad5 HIV Type 1 gag vaccinated human subjects. AIDS Res Hum Retroviruses 2006; 22:1081-1090. (Pubitemid 44904257)
135. Addo MM. YuXG. Rathod A et al. Comprehensive epitope analysis of human immunodeficiency virus rype 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77:2081-2092. (Pubitemid 36110021)
136. Betts MR. Ambrozak DR. Douek DC et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 200l; 75:11983-11991.
137. Brander C. Frahm N, Walker BD. The challenges of host and viral diversity in HIV Vaccine design. Curr Opin Immunol 2006: 18:430-437. (Pubitemid 43947582)
138. Sadagopal S, Amara RR, Montefiori DC et al. Signature for long-term Vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge:stable low-breadthand low-frequency T-cell response capable of coproducing gamma interferon and interleukin-Z, J Virol 2005: 79:3243-3253. (Pubitemid 40327914)
139. Dunham R. Pagliardini P. Gordon S et al. The AIDS resistance of naturally SIV-infected soory mangabeys is independent of cellular Immunity to the virus. Blood 2006; 108:209-217. (Pubitemid 43990631)
140. Maetapallil JJ. Douek DC. Buckler-White A et al. Vaccination preserves CD4 memory T-cells during acute simian immunodeficiency virus challenge. J Exp Med 2006 ; 203: 1533-1541. (Pubitemid 43877613)
141. Casimiro DR. Chen L. Fu TM et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid. recombinant vaccinia virus and replication-defective adenovirus vectors expressing a human immunodeficienc y virus type 1 gag gene.J Virol 2003; 77:6305-6313. (Pubitemid 36588400)
142. Shiver JW; Fu TM. Chen L et al. Replication -incompetent adenoviral Vaccine vecto r elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415 :331-335. (Pubitemid 34087555)
143. Casimiro DR. Wang F, Schleif WA et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immun ization with dna and recombinant adenoviral Vaccine vectors expressing Gag.J Virol 2005; 79:15547-15555. (Pubitemid 43032336)
144. McDermott AB. O'Connor DH. Fuenger S et al. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus -boosted and DNA-primed Mamu-A'01-positive rhesus macaques. J Virol 2005; 79:15556-15566. (Pubitemid 43032337)
145. HIV Vaccine failure prompts Merck to halt trial. Nature 2007; 449 :390.
146. Cohen J. AIDS research. Promising AIDS Vaccine 's failure leaves field reeling, Science, 2007, 318: 28-29 (Pubitemid 47538010)
147. Betts MR. Exley B. Price DA et al. Characterization of functional and phenotypic changes in anti-Gag Vaccine -induced T-cell responses and their role in protection alter HIV-1 infection. Proc Nad Acad Sci USA 2005 ; 102:4512-4517. (Pubitemid 40397143)
148. Staprans SI. Barry AP. Silvestri G et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T-cell response to the SIV envelope protein. Proc Nad Acad Sci USA 2004; 101:13026-13031. (Pubitemid 39167577)
149. Graham BS. Infection with HIV-1. BMJ 1998; 317:1297-1301.
150. Mascola JR, Snyder SW; Weislow OS et al. Immunization with envelope subunit Vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996; 173:340-348. (Pubitemid 26042433)
151. Jeffs SA. Goriup S. Kebble B et al. Expression and characterisation of recombinant oligomeric envelope g1ycoproteins derived from primary isolates of HIV-1. Vaccine 2004; 22:1032-1046. (Pubitemid 38221097)
152. Stott EJ. Almond N. Kent K et al. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) Vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. J Gen Virol 1998; 79(Pt 3):423-432. (Pubitemid 28115864)
153. Ferranrelli F, Cafaro A. Ensoli B. Nonstructural HIV proteins as targets for prophylactic or therapeutic Vaccines. Curr Opin Biotechnol 2004 ; 15:543-556. (Pubitemid 39551007)
154. Flynn NM. Forthal DN. Harro CD et al. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 Vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
155. Pirisuttirhum P.Gilbert P. Gurwith M et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recomb inant glycoprotein 120 HIV-1 Vaccine among injection drug users in Bangkok. Thailand. J Infect Dis 2006; 194:1661-1671. (Pubitemid 44901996)
156. VaxGen 2007 (http://www.vaxgen.com).
157. Haynes BF. Montefiori DC. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 Vaccine candidates. Expert Rev Vaccines 2006 ; 5:579-595. (Pubitemid 44627888)
158. Letvin NL. Barouch DH. Montefiori DC. Prospects for Vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 2002 ; 20:73-99. (Pubitemid 34293421)
159. Zolla-Pazner S. Gorny MK. Nyambi PN. The implications of antigenic diversity for Vaccine development. Immunol Lett 1999; 66:159-164. (Pubitemid 29136833)
160. Hansen JE, Clausen H, Nielsen C, et al. Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: Peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization, J Virol , 1990; 64: 2833-2840 (Pubitemid 20171273)
161. Kwong PD. Doyle ML. Casper DJ et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002 ; 420:678-682. (Pubitemid 36764500)
162. Reitter JN. Means RE. Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med, 1998, 4: 679-684.
163. Wyatt R. Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigen s and immunogens. Science 1998; 280 :1884-1888. (Pubitemid 28299385)
164. Beddows S. Kirschner M. Campbell-Gardener L et al. Construction and characterization of soluble. cleaved and stabilized trirneric Env proteins based on HIV type 1 Env subtype A. AIDS Res Hum Retroviruses 2006 ; 22:569-579.
165. Kirschner M. Monrose V. Paluch M et al. The production of cleaved. trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein Vaccine antigens and infectious pseudoviru ses using linear polyethylenimine as a transfection reagent. Protein Expr Purif 2006 ; 48:6 1-68.
166. Richardson TM Jr. Stryjcwski BL. Broder CC et al. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.J Virol 1996; 70:753-762. (Pubitemid 26028990)
167. Yang X, Wyan R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trirners. J Virol 2001; 75 :1165-1171.
168. Buckner C. Gines LG, Saunders CJ et al. Priming B-cell-medlared anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 2004; 320:167-180. (Pubitemid 38296723)
169. Cherpelis S. Shrivastava I, Genie A et al. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) Tvcell-deplered rhesus macaques.J Virol 2001 ; 75:1547-1550. (Pubitemid 32094712)
170. Beddows S, Franti M, Dey AK et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolyrically cleaved, soluble trimeric human immunodeficiency virus type 1 gp 140. trimeric cleavage- defective gp140 and monomeric gp120. Virology 2007 ; 360:329-340. (Pubitemid 46482615)
171. Center RJ, Lebowitz J, Lcaprnan RD, et al. Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras, J Virol. 2004,78: 2265-2276 (Pubitemid 38228920)
172. Chakrabarti BK, Kong WP, Wu BY et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.J Virol 2002; 76:5357-5368. (Pubitemid 34517886)
173. Srivastava IK, Stamatatos L. Legg H et al. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol 2002 ; 76:2835-2847. (Pubitemid 34184870)
174. Yang X. Farzan M, Kolchinsky P et al. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. JVirol 2000 ; 74:4746-4754. (Pubitemid 30237902)
175. Yang X, Lee J, Mahony EM et al. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif ofT4 bacteriophage fibritin. J Virol 2002; 76:4634-4642. (Pubitemid 34309599)
176. Zhang CW; Chishti Y, Hussey RE et al. Expression, purification and characterization of recombinant HIV gpl40. The gp41 ectodornain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer J Biol Chern 2001 ; 276:39577-39585.
177. Barnett SW; Lu S. Srivastava I et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.J Virol 2001; 75:5526-5540. (Pubitemid 32488146)
178. Bower JF, Yang X, Sodroski J, et al. Elicitation of neutralizing antibodies with DNA Vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d, J Virol, 2004, 78: 4710-4719 (Pubitemid 38501092)
179. Kim M. Qiao ZS, Montefiori DC et al. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trirners as immunogens for the induction of neutralizing antibodies. AIDS Res Hum Retroviruses 2005 ; 21:58-67. (Pubitemid 40179802)
180. VanCott TC, Mascola JR. Kaminski RW et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.J Virol 1997; 71:4319-4330. (Pubitemid 27204119)
181. Binley JM, Sanders RW; Clas B et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion -associated srructure.J Virol 2000; 74:627-643. (Pubitemid 30036198)
182. Sanders RW; Vesanen M, Schuelke N et al. Stabilization of the soluble, cleaved , trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002; 76 :8875-8889. (Pubitemid 34864082)
183. Schulke N. Vesanen MS, Sanders RW et al. Oligomeric and conformational properties of a proteolytically mature. disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.J Virol 2002 ; 76:7760-7776. (Pubitemid 34760999)
184. Beddows S. Schulke N. Kirschner M et al. Evaluating the immunogenicity of a disulfide-stabilized. cleaved. trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005 ; 79:8812-8827. (Pubitemid 40934792)
185. Billington J, Hickling TP, Munro GH, et al. Stability of a receptor-binding active human immunodeficiency virus type 1 recombinant gp140 trimer conferred by intermonorner disulfide bonding of the V3 loop: differential effects of protein disulfide isomerase on CD4 and coreceptor binding, J Virol, 2007, 81: 4604-4614 (Pubitemid 46668658)
186. Dey AK, David KB, Klasse PJ et al. Specific amino acids in the Nsterminus of the gp41 ectodomain contribute co the stabilization of a soluble, cleaved gpl40 envelope glycoprotein from human immunodeficiency virus type 1. Virology 2007; 360:199-208.
187. Forsell MN, Li Y,Sundback M et al. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. J Virol 2005; 79:10902-10914. (Pubitemid 41170632)
188. Yang X, Kurteva S, Ren X et al. Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. J Virol 2006; 80:4388-4395.
189. Barnett SW; Srivastava IK, Ulmer JB et al. Development of V2-deleted trimeric envelope Vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes Band C. Microbes Infect 2005; 7:1386-1391. (Pubitemid 41655968)
190. SrivastavaIK, Stamatatos L, Kan E et al. Purification, characterization and immunogenicity of a soluble crimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-cropic human immunodeficiency virus type 1 Isolate.J Virol 2003; 77:11244-11259. (Pubitemid 37204314)
191. SrivastavaIK, VanDorsten K, Vojtech L et al. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.J Virol 2003; 77:2310-2320. (Pubitemid 36222754)
192. Devico A, SilverA, Thronton AM et al. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. Virology 1996; 218:258-263.
193. Fouts T, Godfrey K, Bobb K et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci USA 2002; 99:11842-11847. (Pubitemid 34994486)
194. Wahren B, Liu M. Therapeutic vaccination against HIV. Expert Rev Vaccines 2004; 3:S179-S188. (Pubitemid 39120636)
195. Tavel JA, Martin JE, Kelly GG et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA Vaccine administered by a needle-free device in HIV-1 -seronegative subjects. J Acquir Immune Defic Syndr, 2007, 44: 601-605 (Pubitemid 46594906)
196. Barouch DH, Kunstman J, Kuroda MJ et al. Eventual AIDS Vaccine failure in a rhesus monkey by viral escape from cytotoxic T-lymphocytes. Nature 2002; 415:335-339. (Pubitemid 34087556)
197. Barouch DH, Kunstrnan J, GlowczwskieJ et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T-lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003; 77:7367-7375. (Pubitemid 36734505)
198. Burro S, Fiorelli V, Tripiciano A et al. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans and South Africans. J Infect Dis 2003; 188:1171-1180. (Pubitemid 37338982)
199. Robert-GuroffM. HIV regulatory and accessory proteins: new targets for Vaccine development. DNA Cell Biol 2002; 21:597-598. (Pubitemid 35155681)
200. Wu Y,Marsh JW. Selective cranscription and modulation of resting T-cell activity by preinregrared HIV DNA. Science 2001; 293:1503-1506. (Pubitemid 32801554)
201. Addo MM, Altfeld M, Rosenberg ES et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T-lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001; 98:1781-1786. (Pubitemid 32165575)
202. Addo MM, Yu XG, Rosenberg ES et al. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol 2002; 21:671-678.
203. Liu Z, Xiao Y,Chen YH. Epitope-Vaccinestrategy against HIV-1: today and tomorrow. Immunobiology 2003; 208:423-428. (Pubitemid 38081365)
204. YuXG, Lichterfeld M, Addo MM et al. Regulatory and accessory HIV-1 proteins: potential targets for HIV-1 Vaccines? Curr Med Chem 2005; 12:741-747. (Pubitemid 40331063)
205. Bobbitt KR, Addo MM, Altfeld M et al. Rev activity determines sensitivity of HIV-1-infecred primary T-cells to CTL killing. Immunity 2003; 18:289-299. (Pubitemid 36266688)
206. Li L, Li HS, Pauza CD et al. Roles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactions. Cell Res 2005; 15:923-934. (Pubitemid 41826262)
207. Seelamgari A, Maddukuri A, Berro R et al. Role of viral regulatory and accessory proteins in HIV-1 replication. Front Biosci 2004; 9:2388-2413.
208. Joseph AM, Kumar M, Mirra D. Nef: "necessary and enforcing factor" in HIV infection. Curr HIV Res 2005; 3:87-94. (Pubitemid 40081288)
209. Caputo A, Gavioli R, Ensoli B. Recent advances in the development of HIV-1 Tat-based Vaccines. Curr HIV Res 2004; 2:357-376. (Pubitemid 39242966)
210. HuangL, Bosch I, Hofmann W et al. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol 1998; 72:8952-8960. (Pubitemid 28471839)
211. Secchiero P, Zelia D, Capitani S et al. Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T-cells. J Immunol 1999; 162:2427-2431. (Pubitemid 29288872)
212. Fanales-Belasio E, Moretti S, Nappi F et al Native HN-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function and antigen-specific T-cell responses. J Immunol 2002; 168:197-206. (Pubitemid 34014119)
213. Kim DT. Mitchell DJ, Brockstedt DG et al. Introduction of soluble proteins into the MHC class 1 pathway by conjugation to an HIV tat peptide. J Immunol 1997; 159:1666-1668. (Pubitemid 127484150)
214. Moy P. Daikh Y, Pepinsky Bet al. Tat-mediated protein delivery can facilitate MHC class 1 presentation of antigens. Mol Biotechnol 1996; 6:105-113. (Pubitemid 126440704)
215. Gavioli R. Gallerani E, Fortini C et al. HIV-1 tat protein modulates the generation of cytotoxic Tvcell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 2004; 173:3838-3843. (Pubitemid 39280746)
216. Rernoli AL. Marsili G, Perrotti E et al. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biocheml 2006; 396:371-380. (Pubitemid 43837253)
217. Allen TM. Alrfeld M, Yu XG et al. Selection. transmission and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol 2004 ; 78:7069-7078. (Pubitemid 38781545)
218. Yokomaku Y,Miura H, Tomiyama H et al.Impaired processingand presentation ofcytotonc-Tdymphocyre (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection. J Virol 2004; 78:1324-1332. (Pubitemid 38095842)
219. Gavioli R, Cellini S. Castaldello A et al. The Tat protein broadens Tvcell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Vaccine 2008; 26:727-737.
220. Gruters RA. van Baalen CA, Osterhaus AD. The advantage of early recognition of HIV-infecred cells by cytotoxic Tdymphocytes. Vaccine 2002; 20:2011-2015. (Pubitemid 34450804)
221. Allen TM. O'Connor DH, Jing P et al. Tat-specific cytotoxic T-lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386-390.
222. Loffredo JT, RakaszEG. GiraldolP et al Tat(28-35)SL8-specific CD8+ T-lymphocytes are more effective than Gag(181-189)CM9-specific CD8+ Tdymphocytes at suppressing simian immunodeficiency virus replication in a functional in vitro assay. J Virol 2005; 79: 14986-14991. (Pubitemid 41636298)
223. O'Connor DH. Allen TM, Vogel TV et al. Acute phase cytotoxic T-lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 2002; 8:493-499. (Pubitemid 34546752)
224. O'Connor DH. Mothe BR, Weinfurrer IT et al. Major histocompatibility complex class 1 alleles associated with slow simian immunodeficiency virus diseaseprogression bind epitopes recognized by dominant acute-phase cyrotoxic-Tdympho cyte responses. J Virol 2003; 77:9029-9040. (Pubitemid 36936111)
225. van Baalen CA. Pontesilli O. Huisman RC et aLHuman immunodeficiency virus type 1 Rev-and Tat-specific cytotoxic T-lymphocyte frequencies inverselycorrelate with rapid progression to AIDS. J Gen Virol 1997; 78(Pt 8):1913-1918. (Pubitemid 27367674)
226. Venet A, Bourgault I, Aubertin AM et al. Cytotoxic T-lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques. J Immunol 1992; 148:2899-2908.
227. Re MC. Furlini G, Vignoli M et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. Acquir Immune Defic Syndr Hum RetroVirol 1995; 10:408-416.
228. Reiss P, Lange JM. de Ronde A et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol 1990; 30:163-168. (Pubitemid 20146235)
229. Rezza G, Fiorelli V, Dorrucci M et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters, J Infect Dis 2005; 191:1321-1324.
230. Rodman TC. To SE, Hashish H et al. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci USA 1993; 90:7719-7723. (Pubitemid 23250022)
231. Zagury D, Lachgar A, Chams V et al. Interferon alpha and Tat involvement in the immunosuppression of uninfec ted T-cells and C-C chernokine decline in AIDS. Proc Natl Acad Sci USA 1998; 95:3851-3856. (Pubitemid 28173217)
232. Cafaro A. Caputo A, Fracasso C et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein Vaccine . Nat Med 1999; 5:643-650. (Pubitemid 29289427)
233. Cafaro A. Titti F. Fracasso C et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 2001; 19:2862-2877. (Pubitemid 32244279)
234. Goldstein G, Manson K, Tribbick G et al. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peprides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine 2000; 18:2789-2795. (Pubitemid 30254464)
235. Maggiorella MT, Baroncelli S, Michelini Z et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004; 22:3258-3269. (Pubitemid 39078741)
236. Pauza CD, Trivedi P, Wallace M et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Nad Acad Sci USA 2000; 97:3515-3519. (Pubitemid 30183334)
237. Allen TM, Mortara L, Mothe BR et al.Tat-vaccinatedmacaquesdo not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002; 76:4108-4112. (Pubitemid 34250576)
238. Liang X, Casimiro DR, Schleif WA et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A'01-negative rhesus monkeys.J Virol 2005; 79:12321-12331. (Pubitemid 41346094)
239. Silvera P, Richardson MW, Greenhouse J et al. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol 2002; 76:3800-3809. (Pubitemid 34250545)
240. Titti F, Cafaro A, Ferrantelli F et al. Problems and emerging approaches in HIV/AIDS Vaccine development. Expert Opin Emerg Drugs 2007; 12:23-48. (Pubitemid 46499494)
241. Michienzi A, Dc Angelis FG, Bozzoni I et al. A nucleolar localizing Rev binding element inhibits HIV replication. AIDS Res Ther 2006; 3:13.
242. de Oliveira T, Salemi M, Gordon M et al. Mapping sites of positive selection and amino acid diversification in the HIV genome: an alternative approach to Vaccine design? Genetics 2004; 167:1047-1058. (Pubitemid 39045616)
243. Osterhaus AD, van Baalen CA, Gruters RA et al. Vaccination with Rev and Tat against AIDS. Vaccine 1999; 17:2713-2714. (Pubitemid 29314468)
244. Calarota S, Bran G, Nordlund S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351:1320-1325. (Pubitemid 28195910)
245. Calarota SA, Leandersson AC, Bratt G et al. Immune responses in asymptomatic HIV-1intecced patients after HIV-DNA immunization followed by highly active anti-retroviral treatment. J Immunol 1999; 163:2330-2338. (Pubitemid 29382245)
246. Calarota SA, Weiner DB. Approaches for the design and evaluation of HIV-1 DNA Vaccines . Expert Rev Vaccines 2004; 3:S135-S149. (Pubitemid 39120633)
247. Kaminchik J, Bashan N, Irach A et al. Genetic characterization of human immunodeficiency virus type 1 nef gene products translated in vitro and expressed in mammalian cells. J Virol 1991; 65:583-588.
248. Yu G, Felsred RL. Effect of myristoylation on p27 nef subcellular distribution and suppression of HIV-LTR transcription. Virology 1992; 187:46-55.
249. Piguet V, Schwartz O, Le GS et al. The downregulation of CD4 and MHC-1 by primate lenriviruses: a paradigm for the modulation of cell surface receptors. Immunol Rev 1999; 168:51-63. (Pubitemid 29276672)
250. Arold ST, Baur AS. Dynamic Nef and Nef dynamics: how structure could explain the complex activities of this small HIV protein. Trends Biochem Sci 2001; 26:356-363. (Pubitemid 32530653)
251. Fackler OT, Baur AS. Live and let die: Nef functions beyond HIV replication. Immunity 2002 ; 16:493-497. (Pubitemid 34442574)
252. Qiao X, He B, Chiu A et al. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B-cells. Nat Immunol 2006; 7:302-310.
253. Sol-Foulon N, Moris A, Nobile C et al. HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity 2002; 16:145-155. (Pubitemid 34143224)
254. Quaranta MG. Mattioli B, Giordani L et al. The immunoregulatory effects of HIV-1 Nef on dendritic cells and the pathogenesis of AIDS. FASEB J 2006; 20:2198-2208. (Pubitemid 44953849)
255. Xu XN, Screaton GR. Gotch FM et al. Evasion of cytotoxic T-lymphocyte (CTL) responses by nef-dependent induction ofFas ligand (CD95L) expression on simian immunodeficiency virus-Infected cells. J Exp Med 1997; 186:7-16. (Pubitemid 27304842)
256. Geleziunas R. Xu W, Takeda K et al. HIV-1 Nef inhib its ASK1 -dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 2001; 410:834-838.
257. Schiavoni I, Trapp S. SanrarcangeloAC et al. HIV-1 Nef enhances both membrane expression and virion incorporation of Env products. A model for the Net-dependent increase of HIV-1 infectivity 1.J Biol Chern 2004; 279:22996-23006. (Pubitemid 38685602)
258. Asakura Y, Hamajima K. Fukushima J et al. Induction of HIV-1 Nef-specific cytotoxic T-lymphocytes by Nef-expressing DNA Vaccine . Am JHematol 1996; 53:116-117. (Pubitemid 26377697)
259. Cosma A, Nagaraj R, Buhler S et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003; 22:21-29. (Pubitemid 37357149)
260. Muthurnani K, Bagarazzi M, Conway D et al. Inclusion of Vpr accessory gene in a plasmid Vaccine cocktail markedly reduces Nef Vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques. J Med Prirnarol 2002; 31:179-185.
261. Ensoli B. Cafaro A, Caputo A et al. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env, Microbes Infect 2005; 7:1392-1399. (Pubitemid 41653484)
262. Ensoli B. Rational Vaccines trategies against AIDS: background and rationale. Microbes Infect 2005; 7:1445-1452. (Pubitemid 41653491)
263. Ensoli B. Criteria for selection of HIV Vaccine candidates-general principles. Microbes Infect 2005; 7:1433-1435. (Pubitemid 41653489)
264. Erfle V, Goebel FD. Guzman CA et al. Vaccines based on Nefand on Nef/DeltaV2 Env. Microbes Infect 2005; 7:1400-1404. (Pubitemid 41653485)
265. Krohn K. Stanescu I. BlazevicV et al. A DNA HIV-1 Vaccine based on a fusion gene expressing nonstructural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical stud ies. Microbes Infect 2005; 7:1405-1413. (Pubitemid 41653486)
266. Rollman E. Brave A. Boberg A et al. The rationale behind a Vaccine based on multiple HIV antigens. Microbes Infect 2005; 7:1414-1423. (Pubitemid 41653487)
267. Caputo A. Brocca-Cofano E. Castaldello A et al. Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat. gp140 deltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. Vaccine , epub ahead of print.
268. Demberg T, Florese RH, Heath MJ et al. A replicarion-comperent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.J Virol 2007; 81:3414-3427. (Pubitemid 46456650)
269. Sandstrom E, Wahren B. Hejdeman B et al. Improved modes of delivering a safe and highly immunogenic multigene multiclade HIV-1 DNA plasmid Vaccine boosted with HIV-1 MVA (Poster OA02-03, oral presentation, AIDS Vaccine Conference. Seattle. Washington-USA; 2007).
270. Bakari M. The HIVlS project is a north-south collaborative study of the safety and immunogenicity of a multigene, rnulticlade HIV-1 plasmid DNA prime and MVA Vaccine boost (EDCTP Forum. Sweden; http://www.edctp.org/fileadmin/ documents/EDCTP-3rd-Forum-Report-2006.pdf).
271. Fischer W; Perkins S. TheilerJ et al. Polyvalent Vaccines for optimal coverageof potential T-cell epitopes in global HIV-1 variants. Nat Med 2007; 13:100-106. (Pubitemid 46067393)
272. Musey L. Ding Y. Elizaga M et al. HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T-cell immunity in HIV-1-uninfected individuals. J Immunol 2003 ; 171:1094-1101. (Pubitemid 36871427)
273. Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005; 5:783-792. (Pubitemid 41400852)
274. Mampallil JJ, Douek DC, Hill B et al. Massive infection and loss of memory CD4+ T-cells in multiple tissues during acute SIV infection. Nature 2005;
275. VeazeyRS. DeMaria M. Chalifoux LV et al. Gastrointestinal tract as a major site ofCD4+ T-cell depletion and viral replication in SIV infection. Science 1998; 280:427-431. (Pubitemid 28208163)
276. Veazey RS. Marx PA. Lackner AA. Vaginal CD4+ T-cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J Infect Dis 2003; 187:769-776. (Pubitemid 36286937)
277. Bomsel M. Heyman M, Hocini H et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998; 9:277-287. (Pubitemid 28400041)
278. Lo CS. Trabattoni D. Vichi F et al. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfecred heterosexual men. AIDS 2003; 17:531-539. (Pubitemid 36293106)
279. Murphey-Corb M, Wilson LA. TrichelAM et al. Selective induction ofprotective MHC classf-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. J Immunol 1999; 162:540-549. (Pubitemid 29018965)
280. Belyakov IM. Kuznetsov VA. Kelsall B et al. Impact of Vaccine -induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006; 107:3258-3264.
281. Bdyakov IM, Isakov D, Zhu Q et al. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T-cells.J Immunol 2007; 178:7211-7221. (Pubitemid 46847447)
282. Bdyakov IM, Hel Z. KelsallB et al. Mucosal AIDS Vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 2001; 7:1320-1326. (Pubitemid 34007936)
283. Vajdy M. Induction of optimal immune responses against human immunodeficiency virus at mucosal portals of entry. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3:222-233.
284. Kubota M, Miller CJ. Imaoka K et al. Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal 19Aand systemic IgG immune responses in nonhuman primates. J Immunol 1997: 158:5321-5329. (Pubitemid 127681238)
285. Russell MW; MesteckyJ. Humoral immune responsesto microbial infections in the genital tract. Microbes Infect 2002; 4:667-677. (Pubitemid 34607416)
286. Asanuma H. Aizawa C. Kurata T et al. IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and/or subcutaneous administration. Vaccine 1998; 16:1257-1262. (Pubitemid 28308405)
287. Lowell GH, Kaminski RW, VanCott TC et al. Proteosomes, emulsomes and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: induction of serum, intestinal, vaginal and lung IgA and IgG. J Infect Dis 1997; 175:292-301. (Pubitemid 27052234)
288. Bergquist C, Johansson EL, Lagergard T et al. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997; 65:2676-2684. (Pubitemid 27264094)
289. Imaoka K, Miller CJ, Kubota M et al, Nasal immunization of nonhuman primates with simian irnmunode6ciency virus p55gag and cholera toxin adjuvantinduces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol 1998; 161:5952-5958. (Pubitemid 28535963)
290. Medaglini O, Ciabattini A, Cuppone AM et al. In vivo activation of naive CD4+ T-cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii. Infect Immun 2006; 74:2760-2766. (Pubitemid 43672985)
291. Pialoux G, Hocini H, Perusat S et al. Phase 1 study of a candidate Vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegativevolunteers: The ANRS VAC14 study. Vaccine 2007; Epub ahead of print.
292. Vajdy M, Singh M. Intranasal delivery of Vaccines against HIV. Expert Opin Drug Deliv 2006; 3:247-259. (Pubitemid 43338095)
293. Tenner-Racz K, Stahl HC, Uberla K et al. Early protection against pathogenic virus infection at a mucosal challenge site alier vaccination with attenuated simian immunodeficiency virus. Proc Natl Acad Sci USA 2004; 101:3017-3022. (Pubitemid 38327727)
294. Bruhl P, Kerschbaum A, Eibl MM et al. An experimental prime-boost regimen leading to HIV type 1 -speclfic mucosal and systemic immunity in BALB/c mice. AIDS Res Hum Retroviruses 1998; 14:401-407. (Pubitemid 28125698)
295. Eo SK, Gierynska M, Kamar AA et al. Prime-boost immunization with DNA Vaccine: mucosal route of administration changes the rules. J Immunol 2001; 166:5473-5479. (Pubitemid 32374168)
296. Mantis NJ, Kozlowski PA, Mielcarz OW et al, Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies. Vaccine 2001; 19:3990-4001. (Pubitemid 32566324)
297. McCluskie MJ, Weerarna RD, Payette PJ et al. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol Med Microbiol 2002; 32:179-185. (Pubitemid 34270507)
298. Hladik F, Sakchalarhorn P, Ballweber L et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26:257-270. (Pubitemid 46329434)
299. Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T-cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 2001; 13:291-298. (Pubitemid 32537700)
300. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106:255-258. (Pubitemid 32772607)
301. Zhu Q, Thomson CW Rosenthal KL et al. Immunization with adenovirus at the large intestinal mucosa as an effective vaccination strategy against sexually transmitted viral infection. Mucosal Immunol 2008; 1:78-88.
302. Andrieu JM, Lu W. A dendritic cell-based Vaccine for treating HIV infection: background and preliminary results. J Intern Med 2007; 261:123-131. (Pubitemid 46090321)
303. Bozzacco L, Trumpfheller C, SiegalFP et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T-cells in a spectrum of human MHC I haplorypes, Proc Nacl Acad Sci USA 2007; 104:1289-1294. (Pubitemid 46183997)
304. Brown K. Gao W; Alber S et al. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T-cell immunity in monkeys. J Immunol 2003; 171:6875-6882. (Pubitemid 37532123)
305. Carbonneil C, Aouba A, Burgard M et al. Dendritic cells generated in the presence of granulocyte -macrophage colony-stimulating factor and IFN-alpha arc potent inducers of HIV-specific CD8 Tcells. AIDS 2003; 17:1731-1740. (Pubitemid 37000091)
306. Gruber A, Chalmers AS, Rasmussen RA et al. Dendritic cell-based Vaccines trategy against human immunodeficienc y virus clade C: skewing the immune response toward a helper T-cell type 2 profile. Viral Immunol 2007; 20:160-169. (Pubitemid 46608961)
307. Lisziewicz J , Trocio J, Whitman L et al. DermaVir: a novel topical Vaccine for HIV/AIDS. J Invest Dermatol 2005; 124:160-169. (Pubitemid 40100965)
308. Melhem NM, Liu XD, Boczkowski O et al, Robust CD4+ and CD8+ T-cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag. EurJ Immunol 2007; 37:2164-2173. (Pubitemid 47250209)
309. Nehere PN, Nehete BP,Manuri P et al. Protection by dendritic cells-basedHIV synthetic peptide cocktail Vaccine: preclinical studies in the SHIV-rhesus model. Vaccine 2005; 23:2154-2159. (Pubitemid 40341442)
310. Lu W, Wu X, Lu Y et al. Therapeutic dendritic-cell Vaccine for simian AIDS. Nat Med 2003; 9:27-32. (Pubitemid 36098256)
311. Lu W; Arraes LC, Ferreira WT et al. Therapeutic dendritic-cell Vaccine for chronic HIV-1 infection. Nat Med 2004; 10:1359-1365. (Pubitemid 40022718)
312. Veljkovic V, Prljic J, Veljkovic T. Safety and ethical consideration of AIDS Vaccine . Int Rev Immunol 2004; 23:465-486. (Pubitemid 39287281)
313. Burton DR, Desrosiers RC, Doms RW et al. HIV Vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-236. (Pubitemid 38332116)
314. Hokey DA, Weiner DB. DNA Vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol 2006; 28:267-279. (Pubitemid 44764282)
315. Barouch DH, Craiu A, Kuroda MJ et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA Vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 2000; 97:4192-4197. (Pubitemid 30226109)
316. Lervin NL, Montefiori DC, YasutomiY et al. Potent, protective anti-HIV immune responsesgenerated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997; 94:9378-9383. (Pubitemid 27357837)
317. MacGregor RR, Ginsberg R, Ugen ICEet al. T-cell responses induced in normal volunteers immunized with a DNA-based Vaccine containing HIV-1 env and rev. AIDS 2002; 16:2137-2143. (Pubitemid 35387267)
318. Calarota SA,Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA Vaccine potency through incorporation ofT-helper 1 molecular adjuvants. Immunol Rev 2004; 199:84-99. (Pubitemid 38736766)
319. Lori F, Weiner DB, Calarota SA et al. Cytokine-adjuvanted HIV-DNA vaccination strategies. Springer Semin Immunopathol 2006; 28:231-238. (Pubitemid 44764279)
320. Chen WC, Huang L. Nonviral vector as Vaccine carrier. Adv Genet 2005; 54:315-337.
321. Greenland JR, Liu H, Berry D et al. Beta-amino ester polymers facilitate in vivo DNA transfection and adjuvant plasmid DNA immunization. Mol Ther 2005; 12:164-170. (Pubitemid 40862368)
322. Sumida SM, McKay PF, Truitt DM et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA Vaccines . J Clin Invest 2004; 114:1334-1342. (Pubitemid 40385305)
323. Eller MA, Eller LA, Opollo MS et al. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA Vaccine candidate in healthy Ugandans. Vaccine 2007; 25:7737-7742. (Pubitemid 47588523)
324. Graham BS, Koup RA, Roederer M et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate Vaccine . J Infect Dis 2006; 194:1650-1660. (Pubitemid 44901995)
325. Launay O, Durier C, Desaint C et al, Cellular immune responses induced with dose-sparing intradermal administration of HIV Vaccine to HIV-uninfecred volunteers in the ANRS VAC16 trial. PLoS ONE 2007; 2:e725.
326. Dietrich G, Spreng S, FavreD et al. Live attenuated bacteria as vectors to deliver plasmid DNA Vaccines . Curr Opin Mol Ther 2003; 5:10-19. (Pubitemid 36348207)
327. Daudel D, Weidinger G, Spreng S. Use of attenuated bacteria as delivery vectors for DNA Vaccines . Expert Rev Vaccines 2007; 6:97-110. (Pubitemid 46232483)
328. Schodel F, Curriss R, III. Salmonellae as oral Vaccine carriers. Dev Biol Stand 1995; 84:245-253.
329. Russmann H, Shams H, Poblete F. et al. Delivery of epitopes by the Salmonella type III secretion system for Vaccine development. Science 1998; 281:565-568. (Pubitemid 28357372)
330. Evans DT, Chen LM, Gillis J et al. Mucosal priming of simian immunodeficiency virus-specificcytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella rype III secretion antigen delivery system. J Virol 2003; 77:2400-2409. (Pubitemid 36222763)
331. Konen CN, Lankowski AJ, Scott N et al. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella type III secretion system. Vaccine 2006; 24:6216-6224. (Pubitemid 44247245)
332. Tsunetsugu-YokotaY, Ishige M, Murakami M. Oral attenuated Salmonella enterica serovar Typhimurium Vaccine expressing codon-optimized HIV type 1 Gag enhanced intestinal immunity in mice. AIDS Res Hum Retroviruses 2007; 23:278-286. (Pubitemid 46418341)
333. Joseph J, Saubi N, Pezzac E et al. Progress towards an HIV Vaccine based on recombinant bacillus Calmette-Guerin: failures and challenges. Expert Rev Vaccines 2006; 5:827-838. (Pubitemid 46021059)
334. Honda M, Matsuo K, Nakasone T et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmerre-Guerin vector candidate Vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci USA 1995; 92:10693-10697.
335. Yasutomi Y, Koenig S, Haun SS et al. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T-lymphocytes in rhesus monkeys. J Immunol 1993; 150:3101-3107. (Pubitemid 23127560)
336. Someya K, Cecilia D, Ami Y et al. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif J Virol 2005; 79:1452-1462. (Pubitemid 40459092)
337. Falk LA. Goldenthal KL. Esparza J. et al. Recombinant bacillus Calrnerte-Guerin as a potential vector for preventive HIV type 1 Vaccines . AIDS Res Hum Retroviruses 2000; 16:91-98. (Pubitemid 30060978)
338. Enserink M. Public health. In the HIV era. an old TB Vaccine causes new problems. Science 2007; 318:1059. (Pubitemid 350134873)
339. Paterson Y,Johnson RS. Progress towards the use of Listeria monocytogenes as a live bacterial Vaccine vector for the delivery of HIV antigens. Expert Rev Vaccines 2004; 3:Sll9-S134.
340. Guzman CA. Saverino D. Medina E et al, Attenuated Listeria monocytogenes carrier strains can deliver an HIV-1 gp120 T-helper epitope to MHC class II-restricted human CD4+ T-cells. Eur J Immunol 1998; 28:1807-1814. (Pubitemid 28271696)
341. Paterson Y. Maciag pc. Listeria-based Vaccines for cancer treatment. Curr Opin Mol Ther 2005 ; 7:454-460. (Pubitemid 41489186)
342. Yewdell JW, The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol Rev 2005; 207:8-18. (Pubitemid 41415004)
343. Manohar M. Baumann DO. Bos NA et al. Gut colonization of mice with actA-negative mutant of Listeria mono cytogenes can stimulate a humoral mucosal immune response. Infect Immun 2001 ; 69:3542-3549. (Pubitemid 32493265)
344. Frankel FR. Hegde S. Lieberman J et al. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live Vaccine vector. J Immunol 1995; 155:4775-4782.
345. BoyerJD. Robinson TM. Maciag PC et al. DNA prime Listeria boost induces a cellularimmune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology 2005; 333:88-101. (Pubitemid 40222193)
346. Brocksredr DG. Giedlin MA. Leong ML et al, Listeria-based cancer Vaccines that segregate immunogeniciry from toxicity. Proc Natl Acad Sci USA 2004; 101:13832-13837. (Pubitemid 39298493)
347. Brockstedt DG. Bahjat KS. Giedlin MA et al. Killed but metabolically active microbes: a new Vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med 2005; 11 :853-860. (Pubitemid 41161117)
348. Starks H. Bruhn KW;Shen H et al. Listeria monocytogenes as a Vaccine vector: virulence attenuation or existing anti-vector immunity does not diminish therapeutic efficacy. J Immunol 2004; 173:420-427. (Pubitemid 38797368)
349. YoshimuraK. Jain A. Allen HE et al Selectivetatgeting of anti-tumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res 2006; 66:1096-1104. (Pubitemid 43165978)
350. Jiang S. Rasmussen RA. Nolan KM et al. Live attenuated Listeria monocytogenes expressing HIV Gag: Immunogenicity in rhesus monkeys. Vaccine 2007; 25:7470-7479. (Pubitemid 47484002)
351. Neeson P, Boyer J. Kumar S et al. A DNA prime-oral Listeria boost Vaccine in rhesus macaques induces a SIV-speclfic CD8 T-cell mucosal response characterized by high levels of alpha4beta7 integrin and an effector memory phenot ype. Virology 2006; 354:299-315. (Pubitemid 44559651)
352. Learmont J. Tindall B. Evans L et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992; 340:863-867.
353. Learmont J. Cook L, Dunckley H et al. Update on long-term symptomless HIV type 1 infection in recipients of blood products from a single donor. AIDS Res Hum Retroviruses 1995: 11, 1.
354. Brave A. Gudmundsdotter L. Gasteiger G et al. Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: Study of Immunol ogical memory and long-term toxicology. Infect Agent Cancer 2007; 2:14.
355. Singh M. Jeang KT. Smith SM. HIV Vaccine development. Front Biosci 2005; 10:2064-2081. (Pubitemid 40905286)
356. Gherardi MM. Esteban M. Recombinant poxviruses as mucosal Vaccine vectors. J Gen Virol 2005; 86:2925-2936. (Pubitemid 41555556)
357. de Bruyn G. Rossini AJ. Chiu YL et al. Safety profile of recombinant canarypox HIV Vaccines . Vaccine 2004; 22:704-713. (Pubitemid 38114901)
358. Dorrell L. Williams P. Suttill A et al. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gaglmultiepitope immunogen (MVA-HIVA) in HIV-1-infected persons receiving combination anti-rerroviral therapy. Vaccine 2007 ; 25:3277-3283. (Pubitemid 46527996)
359. Gomez CE, Najera JL. Jimenez EP et al. Head-to-head comparison on the immunogenicity of two HIV/ AIDS Vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gpI20 and HIV-1(IIIB) Gag-Pol-Nef protein s of clade B. Vaccine 2007; 25:2863-2885. (Pubitemid 46412565)
360. Zhang ZQ, Casimiro DR. Schleif WA et al. Early depletion of proliferating B-cells of germinal center in rapidly progressive simian immunodeficiency virus infection. Virology 2007; 361:455-464. (Pubitemid 46574858)
361. Amara RR. Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a mulrlprotein DNA/MVA Vaccine . Science 2001; 292:69-74. (Pubitemid 32289126)
362. Hanke T. Samuel RY, Blanchard TJ et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T-lymphocytes in macaques by using a multiepirope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999; 73:7524-7532. (Pubitemid 29383236)
363. Hel Z. TsaiWP. Thornton A et al. Potentiation ofsimian immunodeficiency virus (SIV)-specificCD4(+) and CD8(+) T-cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.J Immunol 2001; 167:7180-7191. (Pubitemid 33144216)
364. Hel Z. Nacsa J, Tryniszcwska E et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre and posrchallenge CD4+ and CD8+ T-cell responses. J Immunol 2002; 169:4778-4787. (Pubitemid 35217140)
365. Ondondo BO. Yang H. Dong T et al. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T-cell responses. Eur J Immunol 2006; 36:2585-2594. (Pubitemid 44608442)
366. Peters BS,Jaoko W; VardasE et al. Studies of a prophylactic HIV-1 Vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safery and immunogenicity. Vaccine 2007; 25:2120-2127. (Pubitemid 46237679)
367. Harrer E. Bauerle M, Ferstl B et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safery, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 2005; 10:285-300. (Pubitemid 41151035)
368. Franchini G, Gurunathan S. Baglyos L et al. Poxvirus-based Vaccine candidates for HIV: two decades of experience with special emphasis on canatypox vectors. Expert Rev Vaccines 2004; 3:S75-S88. (Pubitemid 39120628)
369. Beukema EL. Brown MP. Hayball JD. The potential role of fowlpox virus in rational Vaccine design, Expert Rev Vaccines 2006; 5:565-577. (Pubitemid 44627886)
370. Hel Z, Nacsa J, Tsai WP et al. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV Vaccine candidates in SIVmac251-infected macaques. Virology 2002; 304: 125-134. (Pubitemid 36062839)
371. Goepfert PA. Horton H. McEltath MJ et al. High-dose recombinant Canatypox Vaccine expressing HIV-1 protein. in seronegative human subjects. J Infect Dis 2005; 192:1249-1259. (Pubitemid 41368426)
372. Thongcharoen P. Suriyanon V, Paris RM et al. A phase 1/2 comparative Vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate Vaccine: ALVAC-HIV (vCPI521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007; 46:48-55. (Pubitemid 47507433)
373. Russell ND. Graham BS, Keefer MC et al. Phase 2 study of an HIV-1 canatypox Vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial, J Acquir Immune Defic Syndr 2007; 44:203-212. (Pubitemid 46292224)
374. Kent SJ, Zhao A. Dale CJ et al. A recombinant avipoxvirus HIV-1 Vaccine expressing interferon-gamma is safe and immunogenic in macaques. Vaccine 2000; 18:2250-2256. (Pubitemid 30136365)
375. Emery S, Workman C, Puis RL et al, Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects. Hum Vaccin 2005; 1:232-238.
376. LevyJA, Autran B, Coueinho R et al. Registration of clinical trials. AIDS 2005; 19:105. (Pubitemid 40409528)
377. Kelleher AD. Puis RL. Bebbington M et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic Vaccine for HIV-1. AIDS 2006; 20:294-297.
378. Kent SJ. Dale CJ, Ranasinghe C et al. Mucosally-adminisrered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant Vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 2005; 23:5009-5021. (Pubitemid 41267029)
379. D Dc Rose R. SullivanMT. Dale CJ et al. Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV Vaccines: implications for future trials. Hum Vaccin 2006; 2:134-136. (Pubitemid 44298031)
380. Natuk RJ, Davis AR. Chanda PK et al. Adenovirus vectored Vaccines . Dev Biol Stand 1994; 82:71-77.
381. Cheng C. Gall JG. Kong WP et al. Mechanism of ad5 Vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 2007; 3:e25.
382. Tan PH. Beutelspacher SC, Xue SA et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 2005; 105:3824-3832. (Pubitemid 40656124)
383. Gomez-Roman YR, Roberr-Guroff M. Adenoviruses as vectors for HIV Vaccines . AIDS Rev 2003; 5:178-185.
384. Barouch DH. Nabel GJ. Adenovirus vector-based Vaccines for human immunodeficiency virus type. Hum Gene Ther 2005; 16:149-156. (Pubitemid 40344207)
385. Peng B, Wang LR. Gomez-Roman YR et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant Vaccines arc better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 2005; 79:10200-10209. (Pubitemid 41098561)
386. Sumida SM. Truitt DM. Lemckert AA et al. Neutralizing antibodies to adenovirus serotype 5 Vaccine vectors arc directed primarily against the adenovirus heron protein. J Immunol 2005; 174:7179-7185. (Pubitemid 40705685)
387. Barouch DH, Pau MG. Custers JH et al, Immunogenicity of recombinant adenovirus serotype 35 Vaccine in the presence of pre-existing anti-AdS immunity. J Immunol 2004; 172:6290-6297. (Pubitemid 38621236)
388. Capone S. Meola A. Ercole BB et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 2006; 80:1688-1699. (Pubitemid 43228711)
389. Lemckert AA. Sumida SM. Holterman L et al. Immunogenicity of heterologous prime -boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 Vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005; 79:9694-9701. (Pubitemid 41022312)
390. Nanda A. Lynch OM. Goudsmit J et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based Vaccines in mice and rhesus monkeys. J Virol 2005; 79:14161-14168. (Pubitemid 41552714)
391. Roberts OM. Nanda A. Havenga MJ et al. Heron-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006 ; 441:239-243.
392. Xin KQ, Jounai N. Someya K et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 2005; 12:1769-1777. (Pubitemid 41760289)
393. von Bubnoff A, One-two combination, Heterologous prime-boost is currencly the regimen of choice for many AIDS Vaccine approaches, even though exacclyhow it works is still far from clear. IAVI Report. 2007; Vol 11(3): 11-14.
394. Thorner AR. Lemckcrc AA. Goudsmit J et al. Immunogenicity of heterologous recombinant adenovirus prime-boost Vaccine regimens is enhanced by circumventing vector cross-reactivity. J Viral 2006; 80:12009-12016. (Pubitemid 44904350)
395. Data from STEP study presented at open scientific session confirm Merck's investigational HIV Vaccine was not effective. http://www.merck.com/newsroom/ press-releases/research-and-development/2007-1107.html,accessed on November 9. 2007.
396. Seaman MS. Xu L. Beaudry K et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005; 79:2956-2963. (Pubitemid 40270574)
397. Malkevicch NV. Robert-Guroff M. A call for replicating vector prime-protein boost strategies in HIV Vaccine design. Expert Rev Vaccines 2004; 3:S105-S117. (Pubitemid 39120631)
398. Buge SL. Richardson E.A. Jipanah S et al. An adenovirus-simian immunodeficiency virus env Vaccine elicits humoral. cellular and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 1997; 71:8531-8541. (Pubitemid 27446435)
399. Buge SL. Murry L. Arora K et al. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SN) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. J Virol 1999; 73:7430-7440. (Pubitemid 29383227)
400. Lubeck MD. Natuk R. Myagkikh M et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 1997; 3:651-658. (Pubitemid 27264975)
401. Malkevitch N. Patterson LJ. Aldrich K et al. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting Vaccine regimen induces broad. persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A'01 rhesus macaques. J Immunol 2003; 170:4281-4289. (Pubitemid 36428196)
402. Patterson LJ. Malkevitch N. Pinczewski J et al. Potent. persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev. gag and/or nef Vaccines and boosted with SIV gp120. J Virol 2003 ; 77:8607-8620. (Pubitemid 36936072)
403. Pinczewski J. Zhao J. Malkevitch N et al. Enhanced immunity and protective efficacyagainst SIVmac251 intrarecral challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE. ViralImmunol 2005 ; 18:236-243. (Pubitemid 40586462)
404. Zhao J. Voltan R. Peng B et al. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology 2005; 342:1-12. (Pubitemid 41531981)
405. Zolla-Pazner S, Lubeck M, Xu S et al. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost Vaccine regimen in chimpanzees. J Virol 1998; 72:1052-1059. (Pubitemid 28116884)
406. Johnson PR, Schnepp BC. Connell MJ et al. Novel adeno-associated virus vector Vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005; 79:955-965. (Pubitemid 40053879)
407. Lai CM. Lai YK. Rakoczy PE. Adenovirus and adeno-associaced virus vectors. DNA Cell Biol 2002; 21:895-913.
408. van Lunzen J. Mehendale S. Clumeck N et al. A phase I to evaluate the safety and immunogenicity of a recombinant adeno-associared virus Vaccine (Abstract #474 presented at the 14th CROI, Los Angeles 2007 http://www. retroconference.org/2007).
409. Lin WW; Karin M. A cyrokine-mediared link becween innate immunity, inllammation and cancer. J Clin Invest 2007; 117:1175-1183. (Pubitemid 46718402)
410. Souza AP. Haut L. Reyes-Sandoval A et al. Recombinant viruses as Vaccines against viral diseases. Braz J Med Biol Res 2005; 38:509-522. (Pubitemid 40691999)
411. Albert ML, Sauter B. Bhardwaj N. Dendritic cells acquire antigen from apoptoric cells and induce class I-restricted CTLs. Nature 1998; 392:86-89. (Pubitemid 28150594)
412. MacDonald GH, Johnston RE. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 2000: 74:914-922. (Pubitemid 30036228)
413. Davis NL. West A, Reap E et al. Alphavirus replicon particles as candidate HIV Vaccines . IUBMB Life 2002 ; 53:209-211. (Pubitemid 34728929)
414. McKenna PM. McGettigan JP. Pomerantz RJ et al. Recombinant rhabdoviruses as potential Vaccines for HIV-1 and other diseases. Curr HIV Res 2003; 1:229-237.
415. Publicover J. Ramsburg E, Rose JK. A single-cycle Vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol 2005; 79:13231-13238. (Pubitemid 41508138)
416. Egan MA, Chong SY. Rose NF et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 2004: 20:989-1004. (Pubitemid 39369705)
417. Rose NF, Marx PA, Luckay A et al. An effective AIDS Vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001: 106:539-549. (Pubitemid 32879316)
418. Clarke DK. Cooper D, Egan MA et al. Recombinant vesicular stomatitis virus as an HIV-1 Vaccine vector. Springer Semin Immunopathol 2006; 28:239-253. (Pubitemid 44764280)
419. Cooper D. Wright KJ, Calderon PC et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 Vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 2008; 82:207-219. (Pubitemid 350309137)
420. Crotty S, Andino R. Poliovirus Vaccines trains as mucosal Vaccine vectors and their potential use to develop an AIDS Vaccine . Adv Drug Deliv Rev 2004: 56:835-852. (Pubitemid 38520102)
421. Crotty S, Miller CJ, Lohman BL et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol 2001; 75:7435-7452. (Pubitemid 32738002)
422. Mueller S. Wimmer E. Expression of foreign proteins by poliovirus polyprotein fusion: analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames. J Virol 1998; 72:20-31. (Pubitemid 28048809)
423. Murphy CG , Lucas WT, Means RE et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 2000: 74:7745-7754. (Pubitemid 30641618)
424. Kaur A, Sanford HB, Garry D et al. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 2007: 357:199-214. (Pubitemid 44830064)
425. O'Hagan DT, Singh M. Microparticles as Vaccine adjuvants and delivery systems. Expert Rev Vaccines 2003: 2:269-283. (Pubitemid 36559931)
426. O'Hagan DT, Singh M, Ulmer JB. Microparticles for the delivery of DNA Vaccines . Immunol Rev 2004 ; 199:191-200. (Pubitemid 38736772)
427. Johansen P, Men Y. Merkle HP et al. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 2000; 50:129-146. (Pubitemid 30326693)
428. Bowersock TL. HogenEsch H. Suckow M et al. Oral vaccination of animals with antigens encapsulated in alginate microspheres, Vaccine 1999: 17:1804-1811. (Pubitemid 29138921)
429. O'Hagan DT, Singh M, Ulmer JB. Microparticle-based technologies for Vaccines . Methods 2006: 40:10-19. (Pubitemid 44415494)
430. Johansen P. Martinez Gomez JM, Gander B. Development of synthetic biodegradable microparticulate Vaccines: a roller coaster story. Expert Rev Vaccines 2007: 6:471-474. (Pubitemid 47304024)
431. Otten GR, Schaefer M, Doe B et al. Enhanced potency of plasmid DNA microparcicle human immunodeficiency virus Vaccines in rhesus macaques by using a priming -boosting regimen with recombinant proteins. J Virol 2005; 79:8189-8200. (Pubitemid 40853522)
432. Caputo A, Brocca-Cofano E, Casraldello A et al. Novel blocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for Vaccine application. Vaccine 2004; 22:2910-2924. (Pubitemid 38900671)
433. Castaldello A, Brocca-Cofano E, Voltan R et al. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine 2006: 24:5655-5669. (Pubitemid 43928193)
434. Voltan R, Castaldello A, Brocca-Cofano E et al. Preparation and characterization of innovat ive protein-coated poly(methylmethacrylate) core-shell nanoparticles for Vaccine purposes. Pharm Res 2007; 24:1870-1882. (Pubitemid 47389242)
435. Buonaguro L. Buonaguro FM. Tornesello ML et al. High efficient produc tion of Pr55(gag) virus-like: particles expressingmultiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res 2001: 49:35-47. (Pubitemid 32146577)
436. Gheysen D. Jacobs E. de Foresta F et al. Assembly and release of HIV-1 precursor Pr55gag virus-like: particles from recombinant baculovirus-Infected insect cells. Cell 1989: 59:103-112. (Pubitemid 19248562)
437. Young KR. McBurney SP. Karkhanis LV et al. Virus-like particles: designing an effective AIDS Vaccine . Methods 2006; 40:98-117. (Pubitemid 44415502)
438. McBurney SP.Young KR, Nwaigwe CI et al. Lenrivirus-like particles without reverse transcriptase elicit efficient immune responses. Curr HIV Res 2006; 4:475-484. (Pubitemid 44524448)
439. Wagner R, Deml L, Notka F et al. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology 1996; 39:93-103. (Pubitemid 26390700)
440. Sailaja G, Skountzou I. Quan FS et al. Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology 2007 ; 362:331-341. (Pubitemid 46678140)
441. Doan LX, Li M, Chen C et al. Virus -like particles as HIV-1 Vaccines . Rev Med Virol 2005 ; 15:75-88. (Pubitemid 40343192)
442. Buonaguro L. Racioppi L. Torncsello ML et al. Induction of neutralizing antibodies and cytotoxic T-lymphocytes in Balblc mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Res 2002; 54:189-201. (Pubitemid 34327684)
443. Buonaguro L, Visciano ML, Tornesello ML et al. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005 ; 79:7059-7067. (Pubitemid 40677337)
444. Schroder U, Svenson SB. Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/ facty acid lipid suspensions as adjuvants. Vaccine 1999; 17:2096-2103. (Pubitemid 29172383)
445. Buonaguro L. Devito C, Tornesello ML et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti -HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007; 25:5968-5977. (Pubitemid 47082465)
446. Karpenko LI, Ilyichev AA, Eroshkin AM et al. Combined virus-like particle-based polyepitope DNA/ protein HIV-1 Vaccine design, immunogenicity and toxicity studies. Vaccine 2007 ; 25:4312-4323. (Pubitemid 46635937)
447. Paliard X. Liu Y, Wagner R et al. Priming of strong, broad and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T-cells afier admin istration of a virus-like particle Vaccine in rhesus macaques. AIDS Res Hum Retroviruses 2000 ; 16:273-282. (Pubitemid 30111963)
448. Adams SE, Dawson KM. Gull K et al. The expression of hybrid HIV:Ty virus-like particles in yeast. Nature 1987; 329:68-70. (Pubitemid 17125896)
449. Lindenberg CE, Stolte I, Langendam MW et al. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 2002 ; 20:2343-2347. (Pubitemid 34497045)
450. Smith D, Hales G, Roth N et al. A randomized trial of nelfinavir, ritonavir, or delavirdine in combina tion with saquinavir-SGC and stavudine in treatment -experienced HIV-1 -infected patients. HIV Clin Trials 2001; 2:97-107. (Pubitemid 32331418)
451. Nabd GJ. HIV Vaccines trategies. Vaccine 2002; 20:1945-1947.
452. Amara RR, Villinger F. Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNNMVA Vaccine . Vaccine 2002; 20:1949-1955. (Pubitemid 34450793)
453. Goepfert P, Hay C, Frey S et al. HIV-1 DNA prime followed by recombinant MVA boost is well tolerated and immunogenic when administered to healthy HIV-1 seronegative adults in HVTN 065. (Poster OA02-04, oral presentation. AIDS Vaccine Conference, Seattle. Washington-USA; 2007), 2007.
454. Mwau M, Cebere I, Sutton J et al. A human immunodeficiency virus I (HIV-1 ) clade A Vaccine in clinical trials: stimulation of HIV-specific Tvcell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) Vaccines in humans. J Gen Virol 2004 ; 85:911-919. (Pubitemid 38489556)
455. Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol 2001; 22:312-316. (Pubitemid 32675244)
456. Goff SP. Retrovirus restriction factors. Mol Cell 2004; 16:849-859. (Pubitemid 40018396)
457. Koup RA. Safrit JT, Cao Y cr al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Viral 1994 ; 68:4650-4655. (Pubitemid 24183063)
458. Musey L, Hughes J. Schacker T et al. Cyrotoxic-T-cell responses. viral load and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267-1274. (Pubitemid 27461281)
459. Yasutomi Y, Reimann KA, Lord CI et al. Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J Virol 1993; 67:1707-1711. (Pubitemid 23067685)
460. Jin X, Bauer DE, Tunleron SE et al. Dramatic rise in plasma viremia alier CD8(+) T-cell depletion in simian immunodeficiency virus-Infected macaques. J Exp Med 1999; 189:991-998. (Pubitemid 29149355)
461. Schmitz JE. Kuroda MJ. Santra S et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283:857-860.
462. Schmitz JE. Johnson RP. McClure HM et aL Effect of CD8+ lymphocyte depletion on virus containment alier simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239ddta3-vaccinated rhesus macaques. J Virol 2005; 79:8131-8141. (Pubitemid 40853516)
463. Miller CJ, Genesca M. Abel K et al. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol 2007; 81:5024-5035. (Pubitemid 46744414)
464. Schmitz JE. Kuroda MJ. Sanna S et al. Effect ofhumoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 2003; 77:2165-2173. (Pubitemid 36110029)
465. Dittmer U. Brooks DM. Hasenkrug KJ. Requirement for multiple lymphocyte subsets in protection by a live attenuated Vaccine against retroviral infection. Nat Med 1999; 5:189-193. (Pubitemid 29068526)
466. Mao H. Lafont BA. Igarashi T et al.CD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype. J Virol 2005; 79:14887-14898. (Pubitemid 41636286)
467. Qin Z. Richter G. Schuler T et al. B-cells inhibit induction of T-cell-dependenr tumor immunity. Nat Med 1998; 4:627-630. (Pubitemid 28237366)
468. Recher M. Lang KS. Hunziker L et al. Deliberate removal of T-cell help improves virus-neutralizing antibody production. Nat Immunol 2004; 5:934-942. (Pubitemid 39276238)
469. Stager S. Alexander J. Kirby AC et al. Natural antibodies and complement are endogenous adjuvants for Vaccine -induced CD8+ T-cell responses. Nat Med 2003; 9:1287-1292. (Pubitemid 37279852)
470. Zinkernagel RM. Immunity, immunopathology and Vaccines against HN? Vaccine 2002; 20:1913-1917.
471. Guy B, The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007; 5:505-517. (Pubitemid 46925379)
472. Klausner RD. Fauci AS. Corey L et al. Medicine. The need for a global HIV Vaccine enterprise. Science 2003; 300:2036-2039. (Pubitemid 36760117)
473. Ioannidis JP. Rosenberg PS. Goeden JJ et al. Effects of CCRS-Delta32. CCR2-641 and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysisof individual-patient data. Ann Intern Med 2001; 135:782-795. (Pubitemid 33051262)
474. Martin MP. Gao X. LeeJH et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-434. (Pubitemid 35154456)
475. Lopalco L. BarassiC. Pastori C et al. CCRS-reactiveantibodies in seronegative partners of HN-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol 2000; 164:3426-3433. (Pubitemid 30149010)
476. PastoriC. WeiserB.BarassiC et al. Long-lasting CCR5 internalization by antibodies in a subset oflong-term nonprogressors: a possible protective effect against disease progression. Blood 2006; 107:4825-4833. (Pubitemid 43882634)
477. Belec L. Ghys PD. Hocini H et al. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HN-1) that block viral transcytosis through tight epithelial barriers in highly exposed HN-1-seronegative African women. J Infect Dis 2001; 184:1412-1422. (Pubitemid 33108855)
478. O'Connor GM. Holmes A. Mulcahy F et al. Natural Killer cells from long-term nonprogressor HN patients are characterized by altered phenotype and function. Clin Immunol 2007; 124:277-283. (Pubitemid 47247613)
479. Broliden K. Hinkula J. Devito C et al. Functional HIV-1 specific IgA antibodies in HN-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001: 79:29-36. (Pubitemid 32938205)
480. Kannanganat S. Kapogiannis BG. Ibegbu C et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T-cells coexpressing three cytokines, J Virol 2007: 81:12071-12076. (Pubitemid 47623838)
481. Rezza G. Titti F. Pezzotti P et al. Anti-nef antibodies and other predictors ofdisease progression in HN-1 seropositive injecting drug users.J Biol Regul Homeost Agents 1992; 6:15-20.
482. Inwoley A, Recordon-Pinson P, Dupuis M et al. Cross-clade conservation of HNtype 1 Nef immunodominant regions recognized by CD8+ T-cells of HN type 1 CRF02-AG-infected Ivorian (West Africa).AIDS Res Hum Retroviruses 2005; 21:620-628. (Pubitemid 41113650)
483. Wilson CC. McKinney D. Anders M et al. Development of a DNA Vaccine designed to induce cytotoxic Tdymphocyte responses to multiple conserved epiropes in HIV-1. J Immunol 2003; 171:5611-5623. (Pubitemid 37432853)
484. Brave A. Ljungberg K. Wahren B et al. Vaccine delivery methods using viral vectors. Mol Pharm 2007; 4:18-32.